Economic Analysis of New Single-Inhaler Triple Therapies in Patients with COPD in the UK
Based on this analysis, FF/UMEC/VI is a dominant (improved outcomes with cost savings) treatment option compared with other SITTs for the treatment of patients with COPD in the UK.
Authors
- Alan Martin (ORCID: https://orcid.org/0000-0002-3673-3383)
- David Halpin (ORCID: https://orcid.org/0000-0003-2009-4406)
- Chris Compton (ORCID: https://orcid.org/0000-0002-7564-5343)
- Nancy Risebrough (ORCID: https://orcid.org/0000-0001-6572-3021)
- Yuchen Ge (ORCID: https://orcid.org/0009-0005-0267-8506)
- Afisi Ismaila (ORCID: https://orcid.org/0000-0002-2876-8308)
- Rui Cai (ORCID: https://orcid.org/0000-0002-6499-2091)
- Katrin Haeussler (ORCID: https://orcid.org/0000-0002-3236-2028)
Institutions
- University of Exeter (GB)
- GlaxoSmithKline (United States) (US)
- Imperial Consultants (GB)
- Health Economics and Outcomes Research (United Kingdom) (GB)
- Impact (CA)
- McMaster University (CA)
Publication Details
- Journal
- International Journal of COPD
- Published
- 2025-08-01
- DOI
- https://doi.org/10.2147/copd.s475748
- Primary Topic
- Inhalation and Respiratory Drug Delivery
- Type
- article
- Field-Weighted Citation Impact
- 0.00